The Five-membered Nitrogen Hetero Ring Has Chalcogen As A Ring Member Patents (Class 514/253.1)
-
Patent number: 7247631Abstract: Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b, in association with a therapeutically effective amount of a CCR5 antagonist or preferably further in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed.Type: GrantFiled: May 6, 2003Date of Patent: July 24, 2007Assignee: Schering CorporationInventor: Mark A. Laughlin
-
Patent number: 7241764Abstract: Compounds of general formula:[Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared.Type: GrantFiled: November 5, 2003Date of Patent: July 10, 2007Assignee: AstraZeneca ABInventors: William Brown, Andrew Griffin
-
Patent number: 7238688Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.Type: GrantFiled: October 27, 2004Date of Patent: July 3, 2007Assignee: Schering CorporationInventors: Stuart B. Rosenblum, Qingbei Zeng, Mwangi Wa Mutahi, Robert G. Aslanian, Pauline C. Ting, Neng-Yang Shih, Daniel M. Solomon, Jianhua Cao, Henry A. Vaccaro, Kevin D. McCormick, John J. Baldwin, Ge Li
-
Patent number: 7214679Abstract: Compounds of the formula: wherein the substituents are as defined herein are useful for treating conditions mediated by p38 kinase.Type: GrantFiled: January 13, 2004Date of Patent: May 8, 2007Assignee: Scios, Inc.Inventors: Babu J. Mavunkel, Sundeep Dugar, Gregory R. Luedtke, Xuefei Tan, Glen McEnroe
-
Patent number: 7101885Abstract: The present invention relates to compounds of formula I wherein Ar, Y and G are as defined in the specification, a is 1 to 4, Z and W are carbon or nitrogen and n is 1, 2 or 3; and to pharmaceutical compositions comprising the compound of formula I and a pharmaceutically effective carrier; and to a method useful in treating or preventing in mammals, including humans, a disorder or condition selected from the group consisting of anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder and phobias.Type: GrantFiled: June 15, 2004Date of Patent: September 5, 2006Assignee: Pfizer IncInventors: John Lowe, III, Mark A. Sanner
-
Patent number: 7101886Abstract: This invention relates to compounds of the formula 1 wherein R1, R3, R4, X1, and X2 are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system and other disorders.Type: GrantFiled: November 7, 2003Date of Patent: September 5, 2006Assignee: Warner Lambert CompanyInventors: Stephen Sung Yong Cho, Jamie Marie Singer, James M. Graham, Tracy Fay Gregory, Harry Ralph Howard, Jr., Sham Shridhar Nikam, Michael Anthony Walters
-
Patent number: 7094778Abstract: This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I: wherein X, Y, and Z are O, S or NR5, and the other substituents are as defined in the specification; and prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.Type: GrantFiled: October 14, 2003Date of Patent: August 22, 2006Assignee: Syntex (U.S.A.) LLCInventors: Charles Alois Dvorak, Lawrence Emerson Fisher, Keena Lynn Green, Ralph New Harris, III, Hans Maag, Anthony Prince, David Bruce Repke, Russell Stephen Stabler
-
Patent number: 7087610Abstract: The invention encompasses a series of benzothiazole compounds which inhibit HIV entry and are useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for using these compounds.Type: GrantFiled: May 9, 2005Date of Patent: August 8, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Tao Wang, John F. Kadow, Nicholas A. Meanwell
-
Patent number: 7026314Abstract: Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.Type: GrantFiled: January 15, 2002Date of Patent: April 11, 2006Assignee: AstraZeneca ABInventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
-
Patent number: 6992189Abstract: In its several embodiments, this invention discloses novel processes to prepare the compounds of formula II and formula IV:Type: GrantFiled: March 27, 2003Date of Patent: January 31, 2006Assignee: Schering CorporationInventors: William Leong, Minzhang Chen, Bosco A. D'sa, Man Zhu, Tong Xiao, Xiongwei Shi, Suhan Tang, Dinesh Gala, Andrew J. Goodman, Christopher M. Nielsen, Gary M. Lee, Juan A. Gamboa, Andrew D. Jones
-
Patent number: 6936611Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.Type: GrantFiled: January 12, 2004Date of Patent: August 30, 2005Assignee: Eli Lilly and CompanyInventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson, Peter Robert Guzzo, Michael John Mayer
-
Patent number: 6911448Abstract: The invention relates to a group of novel piperazine and piperidine derivatives of the formula wherein Y is hydrogen, halogen, alkyl (1-3C), or CN, CF3, OCF3, SCF3, alkoxy(1-3C), amino or mono- or dialkyl(1-3C) substituted amino or hydroxy, X is O, S, SO or SO2, ---Z represents —C, ?C or —N, R1 and R2 independently represent hydrogen or alkyl (1-3C), Q is benzyl or 2-, 3- or 4-pyridylmethyl, wich groups may be substited with one or more more substituents from the group halogen, nitro, cyano, amino, mono- or di (1-3C)alkylamino, (1-3C) alkoxy, CF3, OCF3, SCF3, (1-4C)-alkyl, (1-3C)alkylsulfonyl or hydroxy, and salts and prodrugs thereof.Type: GrantFiled: May 10, 2001Date of Patent: June 28, 2005Assignee: Solvay Pharmaceuticals B.V.Inventors: Roelof W. Feenstra, Johannes A. M. van der Heijden, Cornelis G. Kruse, Stephen K. Long, Gustaaf J. M. van Scharrenburg
-
Patent number: 6887870Abstract: Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C—R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl gorup, R1, R2, R3 and R4 are as defined herein, and where X is N. R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.Type: GrantFiled: September 25, 2000Date of Patent: May 3, 2005Assignee: Bristol-Myers Squibb CompanyInventors: Saleem Ahmad, Shung C. Wu, Steven V. O'Neil, Khehyong Ngu, Karnail S. Atwal, David S. Weinstein
-
Patent number: 6875767Abstract: The present invention relates to compounds having the formula I: which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions. The compounds of the present invention are useful in treating angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: June 19, 2002Date of Patent: April 5, 2005Assignee: Merck & Co., Inc.Inventors: Mark T. Bilodeau, George D. Hartman
-
Patent number: 6872724Abstract: The present invention relates to active polymorphs of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.Type: GrantFiled: June 26, 2003Date of Patent: March 29, 2005Assignee: Merck & Co., Inc.Inventors: Matthew M. Zhao, Mark T. Bilodeau
-
Patent number: 6833369Abstract: This invention concerns compounds of formula the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein X is CH or N; R1 is hydrogen, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, mono- or di(C1-6alkyl)amino, Ar1, Ar1NH—, C3-6cycloalkyl, hydroxymethyl or benzyloxymethyl; R2 is hydrogen, C1-6alkyl, amino, aminocarbonyl, mono- or di(C1-6alkyl)amino, C1-6alkyloxycarbonyl, C1-6alkylcarbonylamino, hydroxy or C1-6alkyloxy; R3, R4 and R5 are each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy, trifluoromethyl, nitro, amino, cyano, azido, C1-6alkyloxyC1-6alkyl, C1-6alkylthio, C1-6alkyloxycarbonyl or Het1; is Ar2, Ar2CH2— or Het2; Ar1 and Ar2 optionally substituted phenyl; Het1 and Het2 are optionally substituted monocyclic heterocycles; having angiogenesis inhibiting activity; their preparation, compositions containing them and their use as a medicine.Type: GrantFiled: October 19, 2001Date of Patent: December 21, 2004Assignee: Janssen Pharmaceutica, NVInventors: Raymond Antoine Stokbroekx, Marc André Ceusters, Marcel Jozef Maria Van der Aa, Marcel Gerebernus Maria Luyckx, Marc Willems, Robert W. Tuman
-
Publication number: 20040242589Abstract: The invention relates to novel compounds of formula (I) having affinity for the 5-HT6 receptor preparation, to compositions containing them and their use in the treatment of various disorders, including CNS disoders.Type: ApplicationFiled: February 6, 2004Publication date: December 2, 2004Inventors: Steven Mark Bromidge, Christopher Norbert Johnson, Gregor James MacDonald, Mervyn Thompson, David R Witty
-
Patent number: 6825200Abstract: The present invention a compound represented by the formula (I): where the structural variables R1-R6 are defined herein.Type: GrantFiled: May 6, 2002Date of Patent: November 30, 2004Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Ichiro Shima, Takehiko Ohkawa, Kazuhiko Ohne, Kentaro Sato, Naoki Ishibashi, Kenichiro Imamura
-
Patent number: 6821972Abstract: Compounds of formula (I): and their salts, solvates, hydrates and prodrugs are useful PCP inhibitors, processes for making the same, compositions comprising the same, and methods of treating a PCP-mediated condition or disease using the same.Type: GrantFiled: March 29, 2002Date of Patent: November 23, 2004Assignee: Pfizer Inc.Inventors: Simon Bailey, Paul Vincent Fish, Kim James, Gavin Alistar Whitlock
-
Publication number: 20040186111Abstract: A compound of formula: 1Type: ApplicationFiled: December 19, 2003Publication date: September 23, 2004Inventors: Qun Sun, Laykea Tafesse, Sam Victory
-
Publication number: 20040180878Abstract: The invention relates to compounds of formula: 1Type: ApplicationFiled: January 16, 2004Publication date: September 16, 2004Inventors: Alain Di Malta, Georges Garcia, Richard Roux, Bruno Schoentjes, Claudine Serradeil-Le Gal, Bernard Tonnerre, Jean Wagnon
-
Patent number: 6784173Abstract: Compounds of formula I wherein A, R1 and R2 are defined in the specification. These compounds are useful as HDAC inhibitors. Also disclosed are methods of making and using said compounds.Type: GrantFiled: June 11, 2002Date of Patent: August 31, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Ulrike Leser-Reiff, Tim Sattelkau, Gerd Zimmermann
-
Publication number: 20040138225Abstract: Compounds of general formula (I), wherein R1 is selected from phenyl, pyridinyl, thiophenyl, furanyl, imidazolyl and triazolyl; where each R1 phenyl ring and R1 heteroaromatic ring optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C1-C6 alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo.Type: ApplicationFiled: November 17, 2003Publication date: July 15, 2004Applicant: AstraZeneca ABInventors: William Brown, Christopher Walpole, Niklas Plobeck
-
Publication number: 20040138224Abstract: The present invention relates to pyrrolidine sulfonamides, pharmaceutical compositions containing them and their use as urotensin II antagonists.Type: ApplicationFiled: September 26, 2003Publication date: July 15, 2004Inventors: Dashyant Dhanak, Steven D Knight, Jian Jin, Ralph A Rivero, Anthony Sapienza
-
Publication number: 20040127503Abstract: In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17&bgr;-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17&bgr;-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.Type: ApplicationFiled: November 14, 2003Publication date: July 1, 2004Applicant: Schering CorporationInventors: Kamil Paruch, Timothy J. Guzi
-
Patent number: 6756374Abstract: Disclosed are novel diaminothiazoles of formula wherein R1, R2, R3, R4 and R5 are as herein disclosed. These compounds and their pharmaceutically acceptable salts and esters are selective inhibitors of Cdk4. As such, these compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing the compounds of formula I and their pharmaceutically acceptable salts and esters, as well as intermediates useful in the preparation of the compounds of formula I.Type: GrantFiled: January 9, 2002Date of Patent: June 29, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Li Chen, Qingjie Ding, Paul Gillespie, Kyungjin Kim, Allen John Lovey, Warren William McComas, John Guilfoyle Mullin, Jr., Agostino Perrotta
-
Publication number: 20040087585Abstract: Nobel PDF inhibitors and novel methods for their use are provided.Type: ApplicationFiled: August 28, 2003Publication date: May 6, 2004Inventors: Jia-Ning Xiang, Siegfried B Christensen, Jinhwa Lee, Daniel J Mercer
-
Publication number: 20040082566Abstract: The present invention relates to pyrrolidine sulfonamides, pharmaceutical compositions containing them and their use as urotensin II antagonists.Type: ApplicationFiled: September 26, 2003Publication date: April 29, 2004Inventors: Dashyant Dhanak, Steven D Knight, Jian Jin, Ralph A Rivera, Anthony Sapienza
-
Publication number: 20040067961Abstract: The use of CCR5 antagonists of the formula 1Type: ApplicationFiled: September 23, 2003Publication date: April 8, 2004Inventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli
-
Patent number: 6689765Abstract: The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v, host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV oType: GrantFiled: January 30, 2002Date of Patent: February 10, 2004Assignee: Schering CorporationInventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli
-
Publication number: 20040023981Abstract: The present invention relates to salt forms of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.Type: ApplicationFiled: June 26, 2003Publication date: February 5, 2004Inventors: Yu Ren, Shyam B. Karki, Matthew M. Zhao, Mark T. Bidodeau
-
Publication number: 20040023979Abstract: The present invention relates to a process for preparing substituted thiazolyl-amino pyridines, which are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases.Type: ApplicationFiled: June 26, 2003Publication date: February 5, 2004Inventors: Matthew M. Zhao, Jingjun Yin
-
Publication number: 20040023978Abstract: The present invention relates to orally active salt forms of the mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.Type: ApplicationFiled: June 26, 2003Publication date: February 5, 2004Inventors: Yu Ren, Shyam B. Karki, Matthew M. Zhao, Mark T. Bilodeau
-
Publication number: 20040023980Abstract: The present invention relates to active polymorphs of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.Type: ApplicationFiled: June 26, 2003Publication date: February 5, 2004Inventors: Matthew M. Zhao, Mark T. Bilodeau
-
Publication number: 20040019059Abstract: The present invention is concerned with the compounds of formula 1Type: ApplicationFiled: March 31, 2003Publication date: January 29, 2004Inventors: Eddy Jean Edgard Freyne, Jose Ignacio Andres-Gil, Frederik Dirk Deroose, Davy Petrus Franciscus Maria Petit, Maria Encarnacion Matesanz-Ballesteros, Rosa Maria Alvarez Escobar
-
Publication number: 20040009987Abstract: This invention concerns compounds of formula 1Type: ApplicationFiled: October 19, 2001Publication date: January 15, 2004Inventors: Raymond Antoine Stokbroekx, Marc Andre Ceusters, Marcel Jozef Maria Van der Aa, Marcel Gerebernus Maria Luyckx, Marc Willems, Robert W. Tuman
-
Publication number: 20030220326Abstract: Pharmaceutical compositions containing effective amounts of CDK-inhibiting diaminothiazole compounds of the following formula (where R1 and R2 are as defined in the specification) or their salts, or prodrugs or active metabolites of such compounds or salts, are useful for treating disorders and diseases such as cancer: 1Type: ApplicationFiled: March 13, 2003Publication date: November 27, 2003Inventors: Wesley K.M. Chong, Shao Song Chu, Lin Li, Rohit K. Duvadie, Yi Yang, Wei Xiao
-
Publication number: 20030216386Abstract: The invention relates to isoxazole and oxadiazole compounds of Formulae I and II, 1Type: ApplicationFiled: April 10, 2003Publication date: November 20, 2003Inventors: Michele A. Weidner-Wells, Todd C. Henninger, Dennis J. Hlasta
-
Publication number: 20030216373Abstract: Compounds of the formula (I), or a pharmaceutically acceptable salt, or an in-vivo-hydrolysable ester thereof, 1Type: ApplicationFiled: May 6, 2003Publication date: November 20, 2003Inventors: Michael Barry Gravestock, Michael John Betts, Ian Richard Matthews, David Alan Griffin
-
Patent number: 6638935Abstract: The invention relates to novel pyridine derivatives of formula 1, to their preparation and to their use as medicaments, in particular for treating tumorsType: GrantFiled: July 20, 2001Date of Patent: October 28, 2003Assignee: Zentaris AGInventors: Peter Emig, Eckhard Günther, Bernhard Kutscher, Bernd Nickel, Jürgen Schmidt, Anita Storch
-
Patent number: 6635646Abstract: Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b, in association with a therapeutically effective amount of a CCR5 antagonist or preferably further in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed.Type: GrantFiled: May 1, 2000Date of Patent: October 21, 2003Assignee: Schering CorporationInventor: Mark A. Laughlin
-
Publication number: 20030181460Abstract: This invention concerns compounds of formula 1Type: ApplicationFiled: March 13, 2003Publication date: September 25, 2003Inventors: Raymond Antoine Stokbroekx, Marc Andre Ceusters, Marcel Jozef Maria Van der Aa, Marcel Gerebernus Maria Luyckx, Marc Willems, Robert W. Tuman
-
Publication number: 20030176445Abstract: This invention provides a compound of the formula (I): 1Type: ApplicationFiled: February 13, 2003Publication date: September 18, 2003Applicant: Pfizer Inc.Inventors: Yoshiyuki Okumura, Mitsuhiro Kawamura, Makato Kawai, Noriaki Murase, Takafumi Ikeda
-
Patent number: 6617339Abstract: Compounds of formula (I) as defined herein, or a pharmaceutically acceptable salt, or an in-vivo-hydrolysable ester thereof, are useful as antibacterial agents. Processes for their manufacture and pharmaceutical compositions containing them are described.Type: GrantFiled: December 5, 2000Date of Patent: September 9, 2003Assignee: Syngenta LimitedInventor: Michael Barry Gravestock
-
Publication number: 20030166646Abstract: The present invention relates to the use of 2-amino-thiazoline derivatives of formula (I): 1Type: ApplicationFiled: November 8, 2002Publication date: September 4, 2003Inventors: Antony Bigot, Jean-Christophe Carry, Serge Mignani
-
Patent number: 6596745Abstract: Provided is a method of treating or ameliorating hypertension in an animal comprising administering an effective amount of a compound of formula I:Type: GrantFiled: May 30, 2002Date of Patent: July 22, 2003Assignee: Alteon, Inc.Inventor: Martin Gall
-
Patent number: 6596724Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of oxadiazole, thiadiazole and thiadiazole oxide derivatives of dihydropyridines of Formula I. wherein B is with X being O, S or and X1 is O or S. As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.Type: GrantFiled: July 2, 2001Date of Patent: July 22, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Graham S. Poindexter, Mendi Higgins, James Guy Breitenbucher
-
Publication number: 20030125336Abstract: Pharmaceutically acceptable hydrochloride and hydrobromide salts of Compound A are disclosed, wherein Compound A is of formula: 1Type: ApplicationFiled: May 30, 2002Publication date: July 3, 2003Inventors: Fred J. Fleitz, Daniel E. Petrillo, Yaling Wang, Russell R. Ferlita, David C. Dubost, Joseph D. Armstrong
-
Patent number: 6586424Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: February 1, 2002Date of Patent: July 1, 2003Assignee: Merck & Co., Inc.Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley
-
Patent number: RE39265Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.Type: GrantFiled: November 9, 2000Date of Patent: September 5, 2006Assignee: Aventis Pharmaceuticals Inc.Inventors: Joseph T. Strupczewski, Kenneth J. Bordeau, Edward J. Glamkowski, Yulin Chiang, Grover C. Helsley